source
- Royalty Pharma pays $125M upfront for royalty stake in AstraZeneca’s ATTR drug cliramitugRoyalty Pharma has entered a deal to acquire a royalty interest in a transthyretin amyloidosis drug being developed by AstraZeneca. The agreement involves an upfront payment of $125 million to Neu…
- Arrowhead's gene-silencing therapy shows strong results in two late-stage triglyceride trialsArrowhead Pharmaceuticals reported positive data from its lipid-lowering gene-silencing candidate Redemplo in two late-stage studies. The results suggest the therapy effectively reduces triglyceri…